Table of Contents
<< Previous Issue | Feb 2023 (Vol: 2023, Issue: 2) | Next Issue >> |
- Section: Licensing
-
Takeda Signs US$1.13 B Deal with Hutchmed for Colorectal Cancer Drug
-
Amgen Signs US$2 B Licensing Agreement with Synaffix for Next-Generation ADCs
-
UniQure Pays US$10 M Upfront for Apic Bio’s ALS Gene Therapy
-
Karuna Pays US$15 M Upfront for Goldfinch Bio’s TRPC4/5 Inhibitors
- Section: Mergers & Acquisitions
-
Sun Pharma Acquires Concert Pharmaceuticals to Broaden its Dermatology Portfolio
-
Ono Pharmaceutical Acquires Multiple Research-Stage Oncology Programmes from KSQ Therapeutics